Veradermics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for skin diseases. The company's primary focus is on addressing significant unmet medical needs in the treatment of viral skin infections, such as molluscum contagiosum and common warts. Veradermics' lead product candidate, VD-101, is a proprietary, stable, and standardized topical formulation of cantharidin. This candidate is being developed for the treatment of molluscum contagiosum, a common and highly contagious viral skin infection that primarily affects children and currently lacks widely approved, painless, and effective treatments. The company's approach combines specialized drug delivery technology with established active pharmaceutical ingredients to improve safety, efficacy, and the overall patient experience. By targeting pediatric and adult populations suffering from contagious skin conditions, Veradermics aims to capture a significant share of the dermatology market. The company is led by a management team with extensive experience in clinical development and regulatory pathways within the pharmaceutical sector, focusing on advancing its clinical programs to bring therapeutic solutions to the global market.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!